Categories
Caregivers Finances Medical Experts Medical Update Article Spouse

Financial Toxicity of Cancer Treatment

Financial Toxicity of Cancer Treatment: Dr. Chino Shares Her Story

Dr. Fumiko Chino feature profile

Fifteen years ago, Dr. Fumiko Chino was the art director at an anime company, getting ready to marry the love of her life, when her fiance was diagnosed with cancer.

Today, she’s a radiation oncologist at Memorial Sloan Kettering and studies the impacts financial strain has on cancer patients.

She opens up about her late husband’s diagnosis, the financial toll it had on them, and how she’s determined to help alleviate the financial burden for other patients and their families. 


This interview has been edited for clarity. This is not medical advice. Please consult with your healthcare provider for treatment decisions.



Introduction

I’m a radiation oncologist specializing in the treatment of breast and gynecological cancers at Memorial Sloan Kettering Cancer Center.

I met my husband in 2004. He was diagnosed with cancer in 2005 and died from cancer in 2007.

How did you and your husband meet?

I first met my husband online. We were an early Internet couple. We met on a site called Nerve, which is where the cool kids used to meet to date. 

He was a PhD student in computer science at Rice. We met in Houston, Texas. At the time, I was in entertainment. I worked as an art director [at] an anime company. Most famously, I worked on Sailor Moon.

I called him Mr. Roboto. He’s a computer scientist who specializes in robotics and artificial intelligence-derived motion.

He’s a very frantic guy. He was very driven. He was very passionate about his work and also about music and art. In that way, we kind of really dovetailed.

Dr. Fumiko Chino with late husband Andrew

It was so quick, it was so aggressive, and we were so terrified.

Andrew

Getting the cancer diagnosis

Like many 20-somethings, I was still trying to figure out my life. I was so happy to have met someone that I was in love with [and] that I could envision a future with.

When my husband, at the time boyfriend, was getting sick — he was having nausea, throwing up, [and] losing a lot of weight — we really thought it was not cancer. No one [who’s] young thinks, “Oh, this is cancer.” It’s everything other than cancer.

It took a little bit of time to find his actual diagnosis, [which was] high-grade neuroendocrine carcinoma.

We had just gotten engaged. We were planning our future, our family. It was just devastating. A cancer diagnosis [when you’re young] completely interrupts your plans.

What we didn’t realize was in addition to how emotionally and physically taxing it would be [was] how financially taxing it would be.

He had had a number of false diagnoses before he came up with cancer. He was told he had IBS. He was told he had celiac disease because he had a lot of cyclical nausea, vomiting, [and] weight loss. He ultimately went in for an endoscopy [and] they didn’t find anything.

They finally did a CT scan and found all of these enlarged lymph nodes throughout his thorax and, particularly, a mass that was compressing his pancreas, which was causing his GI dysfunction.

When they biopsied it, they found that it was not lymphoma, which is what we thought it would be. I knew we were in for a delightful cancer adventure with [an] unknown destination. It was such a long time period between the initial workup and when we actually found out what kind of cancer he had.

We had just gotten engaged. We were planning our future, our family. It was just devastating. A cancer diagnosis [when you’re young] completely interrupts your plans.

We actually jumped ship in Houston and I manifest my own privilege by going to where my mom is a radiation oncologist. We went to her facility to facilitate the workup.

I think like many young people though, it was so quick, it was so aggressive, and we were so terrified.

I remember having [a] discussion about whether or not we should do sperm banking. They said, “It’s going to delay the process of starting chemotherapy by about a week.” It actually takes way less [time] for a guy than it is for a woman, but even that week felt important because you could actually feel the lymph nodes in his neck growing. And so we said, “We won’t do that. We’ll just move forward with chemotherapy.”

He started on a Saturday. In medicine, when I say he started chemo on a Saturday, they’re like, “Oh yeah, they really wanted him to start because no one starts on the weekend.” We were just terrified.

We didn’t realize that insurance was going to be a problem. At that point, insurance had kind of covered everything.

Course of treatment

He started the treatment for intense chemotherapy, platinum-based therapy, on a Saturday. By Monday, when he saw his oncologist, he could feel the difference. It actually responded that quickly, which made us think it was the right thing, even though we knew it was a sacrifice for our imaginary future children.

He went through many, many cycles of that, had a good partial response, and had a little bit of a break. Then [he] had progression and ended up being off therapy for maybe a couple of months tops. He was pretty much always on treatment from the time he was diagnosed until the time he died within a year and a half of his diagnosis.

Dr. Fumiko Chino with late husband Andrew

We didn’t realize that insurance was going to be a problem. At that point, insurance had kind of covered everything.

Dr. Fumiko Chino with late husband Andrew

What was it like being a care partner?

Nobody signs up to be a patient and nobody signs up to be a caregiver but you do it because you’re trying to survive and you’re trying to support the people you love. I was so impressed with him [and] his resilience [in] being able to continue working as a computer scientist through really intensive treatment.

He always said — and this is something that he would have researched so I trust him — that he received more platinum-based therapies than Lance Armstrong did. He had a lot of cycles of chemotherapy.

He had standard nausea, vomiting, [and] weight loss. He had diarrhea, incredible pain, [and] a lot of anxiety. It was this constellation thing, which means that we were in the emergency room all the time. We were admitted to the hospital multiple times.

He dealt with a series of infections and it was just a lot to balance everything. I was still trying to work. I think our income was important to preserve as well.

At one point, I remember he wasn’t answering his phone. I texted him, “Are you doing okay?” He didn’t answer the next. Two hours later, I called him. He didn’t pick up the phone and at this point, it’d been four and a half hours [I’d] been trying to get ahold of him. I ended up actually driving home from work to check on him. He was just doing computer science coding.

Looking back

It’s really interesting because I actually tell my story fairly frequently because it’s a motivator for the research that I do. My spiel is pretty well-polished but sometimes, if I’m trying to provide a little bit more detail or color, I’ll think of a story and it brings up those memories and those hopes and fears that come along with that.

Because I’m interested in oncofertility, [I] just recently realized that that process — the delays, the fear, and also the costs — is a real barrier to a lot of people taking advantage of that. They may end up surviving cancer but then having some other fundamental freedom removed from them.

Trying to be a new widow — I was 29 trying to reinvent myself and my life — was just really challenging.

The aftermath of your partner’s death

There’s no guidebook for great loss and there [are] many manifestations of it. I think it kind of hits you like waves. This is what changed. This is what’s different. This is what my future is.

I was uninsured after he died, actually, for almost two years. I lost my health insurance with his loss.

I also lost my purpose. I had these debts. We had moved to Michigan for his faculty job and I was sort of stubbornly sticking out there. I didn’t actually have a support system there either. I coupled one together. Cancer and any serious illness really expose the fault lines.

Nobody really has it together in their 20s anyway. Trying to be a new widow — I was 29 trying to reinvent myself and my life — was just really challenging.

We had his student health insurance from Rice, which basically had a lifetime cap for its payouts for a single diagnosis — something that was allowed before the Affordable Care Act. A single diagnosis would cap it [at] $500,000. And after that, there was no more insurance coverage for that diagnosis. That is something that we met within roughly a year of his diagnosis

Dr. Fumiko Chino with late husband Andrew

Financial toxicity is incredibly common and, unfortunately, it’s going to manifest in someone in your clinic even if you don’t see it.

The first exposure [to] the fact that his health insurance was poor was that he had a cap on his pharmacy payout. That one we ran up pretty quickly, within several months of his diagnosis. It was a $5,000 payout, which is insane because a single cancer medication can sometimes cost $5,000. But we blessedly didn’t find out until later.

When we started having to pay out-of-pocket for his Zofran, Lovenox, medications for his anxiety, [and] pain medication, that’s when we first found out. That was sort of the blood in the water then the sharks come and we were just under.

You hit that cap and suddenly you’re in no man’s land. People will describe this [as going] into the donut hole or they reach some sort of limit and you’re in catastrophic territory.

If physicians and patients are both unwilling to talk about this dirty underbelly of cancer care, then it’ll never be properly addressed.

Dr. Fumiko Chino with late husband Andrew

Financial toxicity of cancer treatment

I always try to highlight financial toxicity. I’ve dedicated my life to researching financial toxicity, access, affordability, and equity. It’s all part of the same sphere. How do we get people the best cancer treatment?

Financial toxicity is incredibly common and, unfortunately, it’s going to manifest in someone in your clinic even if you don’t see it. They are going to see you and if you don’t see them — the whole them, the whole picture for them — you may miss it and you may miss an opportunity to intervene. My baseline is that this is common and you’re going to see it even if you don’t think you’re seeing it.

The second thing I try to emphasize is that there are really discrete effects of financial toxicities on our patients. People are not able to afford their medications. People [have] to skip out on visits. People are not getting the mental health care that they need. They’re not getting the dental or vision care that they need. Sometimes they’re missing scans. And for some people, they’re actually missing treatments.

I always try to emphasize that there are things we can do about them. There are things that we can do on the health policy level, at an institutional level, and within our own clinic to try to improve outcomes for financial toxicity. 

The first step is always just saying it’s okay to talk about it. This is the thing about sexual health or fertility concerns. We need to take the Band-Aid off. We need to say it’s okay to talk about these things. If physicians and patients are both unwilling to talk about this dirty underbelly of cancer care, then it’ll never be properly addressed.

You can start little or you can go big. There’s really everything in between from parking to policy. You can really make your voice heard.

How to dispute cancer care costs

Pick a thing that you want to intervene [in] and then work doggedly towards it. If you want to take one thing — let’s just say parking cost, something that pretty much everyone agrees [is] ridiculous — that can be your advocacy issue.

You can take every meeting from the director of parking services to the CEO of the hospital — if you can get in — and say, “This is why this is important. This is why we need more vouchers. This is why parking decks should be free. This is why parking is a stupid barrier to receiving care.” And yet it truly is.

The reason why I researched parking costs is [that] we were paying $18 a day to park at MD Anderson. No offense to MD Anderson. I lived in Houston for many, many years. I volunteered at the Texas Medical Center. I know that parking is the biggest revenue generator for the Texas Medical Center. Texas is huge. Parking shouldn’t be an obstacle to receiving care.

You can start little or you can go big. You can think, “How do I lobby at the public policy level? How do I get my face in front of senators or representatives that can actually make meaningful change in how health insurance is designed and delivered?”

There’s really everything in between from parking to policy. You can really make your voice heard.

Dr. Fumiko Chino with late husband Andrew
Dr. Fumiko Chino

What inspired you to get into medicine?

I was sleeping on the floor of an ICU on a collapsing air mattress when my husband was during his terminal hospitalization. That was my light bulb moment. I think I should go into medicine because I feel like I can try to make a change.

My initial thought was I’m going to be a nurse. I talked to my sister, who’s a physician, and she said, “You don’t want to go into nursing.” I was like, “They’re great!” And she’s like, “Oh, I agree. They’re like saints. There’s a hierarchy in medicine and physicians are at the top. You as a nurse who is going to be smarter” — as many nurses are — “than the physician who’s telling you what to do, it’s going to make you frustrated. Your personality type does not sit with that so you should be a physician.” I thought about that more and I thought, “You’re right.”

Transitioning into medicine was a challenge. I had to go back to school. I have a Bachelor of Fine Arts degree. I had to do some post-bacc classes, but it was absolutely the right decision for me.

The impact of cancer treatment on Black and Latinx Americans

This system needs to change. There are many social injustices in the world. We can’t fix all of structural racism. We can’t give everyone the world-class education that I have been privileged to [have]. Yet we can make some differences and every little bit helps. It’s all about incremental change.

Honoring Andrew’s memory

I will think about Andrew every single day. The thing is that this is mission-driven research. This is mission-driven care. My care is for the best outcomes for my patients, but for all patients, right?

I can’t save Andrew, but I can maybe make cancer treatment a little easier for the next person.

Dr. Fumiko Chino with late husband Andrew

More Medical Expert Interviews

Dr. Lecia Sequist

Using AI to Detect Lung Cancer Risks With Dr. Lecia Sequist

Using AI to Detect Lung Cancer Risks Dr. Lecia Sequist discusses using AI to detect lung...
Dr. Mark Lewis, Dr. Kerry Rogers, Dr. Ruben Mesa

Trends in Cancer Research 2022

Learn from three of the top cancer specialists about cancer treatment trends, including precision medicine...
Jack Aiello and Dr. Alfred Garfall feature profile

The Role of Bispecific Antibodies in the Treatment of Multiple Myeloma

The Role of Bispecific Antibodies in the Treatment of Multiple Myeloma Hematologist Alfred Garfall, MD, MS...
ASH 2023 multiple myeloma

The Latest in Multiple Myeloma: Understanding Promising Treatment Options

The Latest in Multiple Myeloma: Understanding Promising Treatment Options Patient advocates Cindy Chmielewski and Jack Aiello...

The Latest in Multiple Myeloma with Caitlin Costello, MD

Dr. Costello discusses the latest in multiple myeloma treatment from ASH 2022, including the MAIA...
Categories
Medical Experts Medical Update Article

The Latest in Genetic Testing in 2023

The Latest in Genetic Testing in 2023

Featuring Sue Friedman and Abigail Johnston

Genetic testing can help people understand their risk for cancer, help them make medical decisions and detect cancer early. For those already diagnosed with cancer, genetic testing can play an important role in finding the best treatment options.

Abigail Johnston is a cancer patient advocate living with stage 4 metastatic breast cancer. Abigail has the ATM gene mutation, which carries an increased risk for breast cancer.

Sue Friedman is the founder and executive director of FORCE, Facing Our Risk of Cancer Empowered. Sue founded FORCE after being diagnosed with breast cancer and testing positive for the BRCA2 mutation.

They both attended the San Antonio Breast Cancer Symposium (SABCS) which provides the latest information in research, prevention, diagnosis, and treatment of breast cancer.

In this conversation, they break down what genetic testing is, the different types of genetic tests, what it could mean for you and your family and how to interpret the test results.

Brought to you in partnership with Project Life.

This interview has been edited for clarity. This is not medical advice. Please consult with your healthcare provider for treatment decisions.


Introduction to genetic mutations

Abigail J.: One of the most important things to know when you get a cancer diagnosis is how you’re going to be treated. Learning about your cancer [and] learning about the things that make your cancer unique helps the doctors make the best decisions in order to give you the best medicine that is specifically targeted to the cancer that’s in your body. 

We’re learning a whole lot more. Doctors are learning things all the time about different biomarkers, mutations that they can target, [and] things within your body that respond differently, from one person to another. There are things that can be understood about different patients as groups. 

One of those things are hereditary or germline mutations. These are mutations that come in your DNA. You get one-half of your DNA from your mom, one-half from your dad. Sometimes mutations can be passed down in families. 

At a time of a cancer diagnosis, a lot of times that’s the only time that a family will suddenly find out that there are these sneaky little things going on in their bodies that they have no control over that mean they’re more predisposed to a cancer diagnosis, to diabetes, to heart disease, [or] to all kinds of different things. 

Understanding those mutations in your DNA not only helps the doctors know what medications to pick, but then you can also do family planning. You can inform your families. There’s all kinds of really important things about knowing what is in your DNA. 

Sue, why did you found FORCE?

Abigail J.: I’m super excited to have Sue Friedman here with us today, who is with FORCE, which stands for Facing Our Risk of Cancer Empowered, an organization all about making sure people understand what’s in their DNA and then know what to do with it. Sue, would you tell us why you founded FORCE? Where did it come from?

Sue F.: I was diagnosed out of the blue at age 33 with breast cancer, and I was very proactive with my health. I didn’t have a family history of breast cancer. It wasn’t until after I was diagnosed and actually after I had my initial treatment that I was reading a magazine article about hereditary cancers and about genetic testing for BRCA1 and 2. This was really many years ago, so kind of in the early days of precision medicine. 

In this magazine article, they were talking about BRCA1 and 2 testing and how certain people are more likely to have an inherited mutation that can predispose them to cancer. I’m reading through these red flags, and one of them was young-onset breast cancer. I’m like, “Okay, that’s me. 33 with breast cancer.” 

Then it was talking about a link between other cancers, like ovarian cancer. My paternal grandmother on my father’s side had some kind of abdominal cancer. They said it could be passed on from either side of the family, like you said. Nobody had ever asked me really about my father’s side of the family in medical intake forms. 

All of those things together, and then they were talking about how people of certain ethnicities or groups are more likely to have a mutation, and that included Ashkenazi Jewish people. I was like, “Okay, I’m 3 for 3 here.” But my healthcare team never told me that.

I’m reading [it] in a magazine article, and I said to them, “I want this test.” They were like, “Sure, give us your arm. We’ll pull the blood. We’ll send it in.” Well, they never actually sent it in.

Abigail J.: Wait a minute. They never sent the blood in?

Sue F.: They never sent the blood in. I know.

Abigail J.: Wow.

Sue F.: There was no genetic counseling, and again, this was the early days of genetic testing. I also ended up having a recurrence soon after that. I ended up at a cancer center for a second opinion, and I told them, “I want this test.” They’re like, “Okay, you have to have genetic counseling.”

The idea was, though, to give a voice to a community that didn’t feel they had one. 

Sue F.

I was halfway through chemotherapy when I found out I had a BRCA2 mutation. Suddenly, I had to make other decisions, too.

Sue and family on Halloween of 1997, shortly after starting treatment.

I had had a unilateral mastectomy for treatment, and suddenly I learned my other breast was at really high risk. I didn’t want to go through chemo and treatment again. 

Then they were talking about my ovarian cancer risk. I didn’t think I was done with having children, but I felt like I didn’t want to go through another diagnosis. I had to make these really tough decisions, like do I end my fertility? Take my ovaries out? There really weren’t resources about that.

Abigail J.: Was your medical team helpful in making those decisions?

Sue F.: They were, but because this was such early days in genetic testing, it was a new test. They didn’t have a lot of long-term outcomes, so they’d say, “Well, we think this will lower your risk for ovarian cancer,” which makes sense. “We think removing your other breast is a good idea, but we don’t know. We don’t have long-term outcomes yet.” 

I had to kind of make those decisions in a vacuum, at least an evidence vacuum. There were a lot of other people who I met who had breast cancer, and there were support services and support groups, but most of them weren’t making those decisions with regard to genetic testing and what to do with that risk.

I really felt the need. It was out of my own need that I started FORCE. I started as a lark. I didn’t even have a computer when I was diagnosed. Soon after treatment, I did take out my ovaries. I was newly postmenopausal at 35, so I spent a lot of nights awake with insomnia. 

I’d be on these message boards, talking to other survivors. I started meeting these other people with mutations. Some of them didn’t have cancer, and some of them did, and they really had nowhere to go. That’s kind of why I started FORCE 24 years ago, to give us all a place to go.

Abigail J.: And 24 years.

Sue F.: 24 years. It just grew, and there was such a need. About 5 years into running FORCE, I actually made the very difficult decision to give up my veterinary career to do it full-time because there were a lot of great vets out there, but there was really only one organization providing resources specifically for that community.

Creating the term “previvor”

Abigail J.: I think I read recently that FORCE was behind the term “previvor.” 

Sue F.: We were. One of the members of our community — and she actually happened to be a member of our board of directors — said, “I need a label. What am I? I don’t have cancer, but I know cancer. I lost my mom to cancer at a young age. I’ve lost my breasts to cancer risk. I lost my ovaries to cancer risk, but I don’t have cancer.” She said, “I’m not one for labels, but I need a label for this.” 

What I realized then, too, was that there was this whole group of stakeholders that weren’t part of the conversation. Before I started FORCE, I’d go to support groups. I’d see some of these previvors go, and they were apologetic, like, “I know I don’t belong here. I’m sorry, I don’t have cancer.”

They were always apologizing, and sometimes they weren’t welcomed as stakeholders. 

It was really for that population that FORCE became a real home. We kind of did a search of terms, and we came up with previvor for “survivor of a predisposition to cancer.” Not everybody loves the term, which is fine. The idea was, though, to give a voice to a community that didn’t feel they had one. 

In that regard, whether people love it or we hear people say, “I don’t like the term; stop using the term.” We’re very open to other terms, but it did provide a community and a label for some people who really wanted more.

Breast cancer and hereditary cases

Abigail J.: When you look at the people who have been diagnosed with breast cancer, is hereditary breast cancer something that makes up a lot of the reason for a diagnosis, or is that a small percentage still?

Sue F.: It’s about 10% roughly. Many people don’t know that they have a mutation, but it can affect treatment decisions, it can affect prevention options, and it can affect your family members. It’s not just breast cancer; it’s other cancers as well. Knowing that information can be really important to medical decision-making. 

It’s not like it’s the majority of people with cancer, but when you look across the spectrum of people who have been diagnosed with breast cancer and other cancers, these are often families that have a disproportionate cancer burden.

There are relatives. There’s siblings. There’s parents. There are children and cousins. The burden within some of these families is really, really high.

Abigail J.: Sure, because once you find one incident of hereditary cancer, everybody starts getting tested. In my particular family, when I was diagnosed with ATM — it’s not BRCA. It’s a different, lower, moderate risk for breast cancer. 

I’m 1 of 6. One of my sisters is positive. My mother, my uncle, [and] several of my cousins. We’re pretty sure my grandfather was, but he’s since passed away. That’s only on my mom’s side of the family. That information, I think, is helpful. 

Abigail with her mother, who also had breast cancer.

Reactions to finding out it’s hereditary

Abigail J.: When people find out that their cancer was probably caused by their genes, they have no control over that. Do you find that helps people realize it’s not their fault?

Sue F.: It’s a mixed bag. I know for me it was a little bit of an a-ha, but not everybody gets that answer. Not every 33-year-old with breast cancer gets that. For them, they don’t get that, being able to know. Also, there can be a layer of guilt. There can be a layer of family dynamics. Sometimes the family dynamics that were already at play get heightened because of it. 

Abigail during treatment for breast cancer.

It’s definitely a mixed bag. You’re not just at risk for one type of cancer, but it’s multiple cancers. It’s not always a relief. At the end of the day, people who are born with mutations always had the mutation. If they get to know it, at least they have a little bit of a chance of doing something potentially proactive about it.

Genetic testing

Abigail J.: Let’s just talk about how you find out you have a genetic mutation. You mentioned genetic counselors. I know there’s a couple of people that are typically involved when you want to find out if you have a genetic predisposition for cancer. I assume a doctor has to order a test.

Sue F.: Yes, that’s true.

Abigail J.: And then what happens?

Sue F.: There are a lot of different entrées into finding out that information. One thing we’re seeing more and more of is that people who are diagnosed with cancer — and especially if they’re diagnosed with, in the breast cancer realm, metastatic breast cancer — they may get tumor testing, and the tumor testing may suggest that there’s a mutation. We see that with prostate cancer as well. 

That’s one way to [get to], “I may have an inherited mutation, and I should get genetic testing.” We recommend people talk to an expert in genetics because ordering the test is complicated. It’s not just one test anymore. As you were talking about, it’s not just BRCA1 and 2 anymore. 

There’s at least 20-plus genes that have all been identified and associated with breast cancer, and then other genes associated with colorectal cancer. They now do panel testing. Being able to order the right test and appropriately interpret the results, you want some expertise. 

Sue and family in 1999 after founding FORCE.

Abigail J.: Is that a geneticist? Are you seeing a geneticist? 

Sue F.: Or a genetic counselor. But also, there are oncologists who are highly trained in genetics. There are genetic nurses now. Really, there’s been an expansion of the amount of people who are able to provide that information up front, and then after someone gets a test result, also telling them what it means for themselves, what it means for their family, [and] who else in their family should now get that information. 

The other thing — and this is the group we worry about — is there may be people who test negative, but there may be something still going on in that family. There may be clinical trials that they can join to look for other additional genes, or there may be further testing that would be appropriate for them. We want to make sure that just because someone gets a negative test doesn’t mean that they’re not seeing a genetics expert after that test result as well.

Direct-to-consumer genetic testing

Abigail J.: I know there’s been a whole lot of different genetic-type things in the news: genealogy things, 23andMe.

Sue F.: Yes. That’s the other thing I was going to mention.

Abigail J.: There’s other direct-to-consumer [tests]. Are those as reliable or as helpful as a test that is ordered by a doctor?

Sue F.: The short answer to that is no. Some of the tests, so like the 23andMe test, look for some of the more common mutations found in people of Ashkenazi Jewish descent there.

They, I think, are now reporting out some colorectal cancer mutations. 

They’re testing just a small amount even in BRCA1 and 2. They’re not looking for these other genes, like ATM, PALB2, chek2, and these other genes that can have mutations. It’s not the same. 

Even when the FDA said to 23andMe, “You can report the results of these tests to people,” it came with the caveat that if you do have testing that way, you should follow up with what they would call a “medical-grade test.” That would be from a lab. That is a doctor-ordered test.

Variant of unknown significance

Abigail J.: Sometimes when you have genetic testing, you see on the report a VUS, which is “variant of unknown significance.” What do you do with that?

Sue F.: Again, this is one of the reasons why we tell people, “Go see a genetics expert.” Unfortunately, we’ve seen healthcare professionals who didn’t have training in genetics report those as mutations to people.

A variant of uncertain or unknown significance, or VUS, is a frustrating result because genetic testing most of the time — especially for BRCA1 and 2, some of these newer genes a little less so — will be a, “Yes, you have a mutation,” or, “No, you don’t.” 

Once in a while, you get this inconclusive test result. We haven’t tested enough people. We don’t know. It could be a gene change that’s the difference between two functioning genes, but they function just a little differently, but they still work, versus you have a mutation [that’s] causing cancer. 

There’s really a need for expertise in those situations, because then from there, the best recommendations they make are based on your family history and your personal medical history. You really need someone who has that expertise and training to look at that and see which cancers are related. 

There could be other testing for relatives that’s usually done as research to see if that VUS, or variant of uncertain significance, is tracking with the cancer in the family.

If everybody who’s had cancer in the family also has that same VUS, then that may be a little bit more evidence that this may be what they would call a pathogenic variant or one that’s cancer-causing. 

There have been some research studies trying to classify variants, too. There’s a lot of researchers trying to figure out this frustrating problem. The US results are more common in some of these newer genes that have been newly discovered that they haven’t done as much testing on in some of these panels.

Genetics don’t guarantee you will get cancer

Abigail J.: Important to have an expert in your corner to help explain, even when you’re thinking about a test. Should you get the test? How do you interpret the test? Then you have the test, and it says there’s some genetic mutation. You have some predisposition towards cancer. That doesn’t mean that you’re going to get that cancer, right?

Sue F.: It doesn’t, but your risk may be very high, and it’s really important. The other thing that expanded panel testing has done for us is found all these genes, and they all have different risks. 

It used to be that even BRCA1 and 2 were kind of lumped together, but the risks are a little different for the different cancers. BRCA1, you’re more likely to have ovarian cancer than BRCA2. BRCA2, you’re a little more likely to get pancreatic cancer than BRCA1. 

Sue during treatment in the late ’90s.

They all are different, and the same is true for some of these other genes, like PALB2 and ATM. Fortunately, there are some guideline panels that look through the evidence every year and update those guidelines based on the gene.

It’s really important, too — and this is another reason to see an expert — to make sure that they recognize the gene you have may be different than BRCA1 or 2 and that they may come with a different set of guidelines and recommendations.

 

Resources provided by FORCE

Abigail J.: If there’s a person who is considering genetic testing, has had genetic testing, or has something that’s going on in the family, what can FORCE do for that particular person?

Sue F.: It depends on their circumstance. We have over 300 volunteers with different genes. Some have had cancer, and some have not. We match people by gene mutation, by their cancer diagnosis, their stage, their age if we can, and then geographically. 

We really try and match people as best as we can to someone who’s had a similar situation so that they can talk to a peer who’s been through it. Then we connect them to personalized guidelines and information and even now clinical trials.

We have clinical trials that are embedded to our website based on the gene that someone has, because now there are clinical trials that are open to people with PALB2 or ATM. 

To bring up a different topic, but [there are] people who don’t have inherited mutations but have acquired or somatic mutations that they found from tumor testing or from some of the biomarker testing looking at tumors. 

We know that matching people to these types of specific clinical trials, they’re really looking for that needle in the haystack person, that subgroup of the larger group. It’s important to us to try and match people to clinical trials that they may be really uniquely suited to [in order to] actually fill enrollment and get those answers for themselves and future generations. 

There’s a lot as far as the personalized information, the clinical trials, the support, the resources, [and] paying for care that we try and do and match according to someone’s situation, including their mutation.

Sue and Dan at the welcome reception.

Abigail J.: It’s such a labor of love to be able to give people that information.

Sue F.: Gratifying, too. It really is incredible — and I’m sure you know this — to be able to meet someone who is facing a challenge and be able to provide them with resources that can help them. What’s better than that?

Abigail J.: Absolutely. Thank you for being here today.

Sue F.: Thank you for inviting me.


More Medical Expert Interviews

Dr. Lecia Sequist

Using AI to Detect Lung Cancer Risks With Dr. Lecia Sequist

Using AI to Detect Lung Cancer Risks Dr. Lecia Sequist discusses using AI to detect lung...
Dr. Mark Lewis, Dr. Kerry Rogers, Dr. Ruben Mesa

Trends in Cancer Research 2022

Learn from three of the top cancer specialists about cancer treatment trends, including precision medicine...
Jack Aiello and Dr. Alfred Garfall feature profile

The Role of Bispecific Antibodies in the Treatment of Multiple Myeloma

The Role of Bispecific Antibodies in the Treatment of Multiple Myeloma Hematologist Alfred Garfall, MD, MS...
ASH 2023 multiple myeloma

The Latest in Multiple Myeloma: Understanding Promising Treatment Options

The Latest in Multiple Myeloma: Understanding Promising Treatment Options Patient advocates Cindy Chmielewski and Jack Aiello...

The Latest in Multiple Myeloma with Caitlin Costello, MD

Dr. Costello discusses the latest in multiple myeloma treatment from ASH 2022, including the MAIA...